Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713574 | 0.92 | KDM4E (0.48) | CA12CA1CA2CA4CA6 | |
| SCHEMBL17713572 | 0.82 | L3MBTL1 (0.50) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL30196375 | 0.81 | HDAC3 (0.54) | CA12CA1CA2CA4CA6 | |
| SCHEMBL23409917 | 0.79 | PDE4D (0.49) | TSHRMAPTCTNNB1WNT3AKDM4E | |
| SCHEMBL19283069 | 0.77 | KMT2A (0.47) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11045658 | 0.75 | PDE4D (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29555877 | 0.75 | PDE4D (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL5186546 | 0.75 | PDPK1 (0.54) | HDAC1HDAC8MAPTALDH1A1 | |
| SCHEMBL19838378 | 0.75 | ALDH1A1 (0.64) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11094252 | 0.75 | CA12 (0.57) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2023-01-19 | — | — | US | disclosed |
| WO-2021105641-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2021-06-03 | — | — | WO | disclosed |
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | CA12 4824/4885CA1 4876/4885CA2 1197/4885 |
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | PEX3, NCOA3, NCAPD3 | CA12 1685/4885CA1 4393/4885CA2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.